2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 732

Predictors of Inpatient Mortality in Patients with Systemic Sclerosis: A Case Control Study
Abstract Number: 1392

Predictors of Long-Term Changes in Body Mass Index in Rheumatoid Arthritis
Abstract Number: 2222

Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry
Abstract Number: 121

Predictors of Persistence of Power Doppler Ultrasound Synovitis in Rheumatoid Arthritis Patients in Clinical Remission
Abstract Number: 2754

Predictors of Quality of Life in Behçet’s Syndrome
Abstract Number: 203

Predictors of Radiographic Progression of Interphalangeal Finger Joints in Erosive Osteoarthritis: A Prospective Study
Abstract Number: 2139

Predictors of Radiologic Disease Progression during the Rheumatoid Arthritis Comparison of Active Therapies Trial
Abstract Number: 2901

Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis
Abstract Number: 2651

Predictors of Therapeutic Outcomes in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2587

Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis
Abstract Number: 2648

Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Abstract Number: 689

Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1143

Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users
Abstract Number: 2573

Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling
Abstract Number: 301

Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].